eCite Digital Repository

Technology evaluation: MRA, Chugai

Citation

Ding, C and Jones, G, Technology evaluation: MRA, Chugai, Current Opinion in Molecular Therapeutics, 5, (1) pp. 64-9. ISSN 1464-8431 (2003) [Professional, Non Refereed Article]

Abstract

Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.

Item Details

Item Type:Professional, Non Refereed Article
Research Division:Medical and Health Sciences
Research Group:Pharmacology and Pharmaceutical Sciences
Research Field:Clinical Pharmacology and Therapeutics
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Skeletal System and Disorders (incl. Arthritis)
Author:Ding, C (Professor Chang-Hai Ding)
Author:Jones, G (Professor Graeme Jones)
ID Code:28591
Year Published:2003
Deposited By:Menzies Centre
Deposited On:2003-08-01
Last Modified:2004-03-15
Downloads:0

Repository Staff Only: item control page